The estimated Net Worth of Jason Hoitt is at least 985 千$ dollars as of 19 March 2020. Mr Hoitt owns over 4,500 units of Provention Bio stock worth over 112,410$ and over the last 6 years he sold PRVB stock worth over 281,405$. In addition, he makes 591,332$ as Chief Commercial Officer at Provention Bio.
Mr has made over 6 trades of the Provention Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,500 units of PRVB stock worth 45,000$ on 10 February 2023.
The largest trade he's ever made was selling 7,580 units of Provention Bio stock on 15 July 2019 worth over 115,671$. On average, Mr trades about 1,696 units every 100 days since 2018. As of 19 March 2020 he still owns at least 4,500 units of Provention Bio stock.
You can see the complete history of Mr Hoitt stock trades at the bottom of the page.
Jason Hoitt is the Chief Commercial Officer at Provention Bio.
As the Chief Commercial Officer of Provention Bio, the total compensation of Mr Hoitt at Provention Bio is 591,332$. There are 8 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of 3,959,460$.
Mr Hoitt is 43, he's been the Chief Commercial Officer of Provention Bio since . There are 15 older and 2 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
Jason's mailing address filed with the SEC is C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK, NJ, 07701.
Over the last 6 years, insiders at Provention Bio have traded over 81,606,241$ worth of Provention Bio stock and bought 165,475 units worth 1,543,065$ . The most active insiders traders include Capital (Master), L.P.Sessa...、Nancy Wysenski、Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of 3,621,900$. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth 53,274,152$.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: